SPTX (Seaport Therapeutics) Shareholder Yield % : 0.00% (As of Dec. 2025)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics Shareholder Yield %?

Seaport Therapeutics SPTX +10.37% 11 Shareholder Yield % is 0.00% as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,301 Biotechnology companies, Seaport Therapeutics ranks worse than 76863.87% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Seaport Therapeutics's Shareholder Yield % was 0.00%.


Seaport Therapeutics  (NAS:SPTX) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Seaport Therapeutics Shareholder Yield % Related Terms


Seaport Therapeutics Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics Shareholder Yield % Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
Shareholder Yield %
0.00 0.00

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
Shareholder Yield % 0.00 0.00

SPTX vs LXRX, DRTS, MGTX: Shareholder Yield % Comparison

For the Biotechnology subindustry, Seaport Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seaport Therapeutics Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Seaport Therapeutics's Shareholder Yield % falls into.


SPTX
11GF Score
Seaport Therapeutics Inc SPTX
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics Shareholder Yield % Calculation

Seaport Therapeutics's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0 %+0 %
=0 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 0.00% mean?
Seaport Therapeutics (SPTX) has a Shareholder Yield % of 0.00% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Seaport Therapeutics and its competitors. According to the industry distribution chart, Seaport Therapeutics ranks #999999 out of 1301 companies in the Biotechnology industry.
Is Seaport Therapeutics' Shareholder Yield % too high?
Seaport Therapeutics' current Shareholder Yield % is 0.00%. Based on the distribution chart, Seaport Therapeutics ranks #999999 out of 1301 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' Shareholder Yield % compare to LXRX and DRTS?
According to the Biotechnology industry distribution chart, Seaport Therapeutics ranks #999999 out of 1301 companies for Shareholder Yield %. This places Seaport Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current Shareholder Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current Shareholder Yield % of 0.00%. The current Shareholder Yield % is 0.00%. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current Shareholder Yield % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price